Skip to content
10-Q

Quarterly Report

IMMIX BIOPHARMA, INC. IMMX

0001641172-25-009280

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q1 2025 · Mar 31, 2025 $15.92M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $17.68M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.31M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.69M
Total Liabilities Q1 2025 · Mar 31, 2025 $10.3M
Total Liabilities Q1 2025 · Dec 31, 2024 $9.7M
Current Assets Q1 2025 · Mar 31, 2025 $16.78M
Current Assets Q1 2025 · Dec 31, 2024 $20.2M
Total Assets Q1 2025 · Mar 31, 2025 $19.89M
Total Assets Q1 2025 · Dec 31, 2024 $22.95M
Shares Diluted Q1 2025 · Mar 31, 2024 23.44M sh
Capex Q1 2025 · Mar 31, 2024 $301.91K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.83M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.22
Eps Basic Q1 2025 · Mar 31, 2024 −$0.22
Sga Expense Q1 2025 · Mar 31, 2024 $2.34M
Rd Expense Q1 2025 · Mar 31, 2024 $3.25M
Net Income Q1 2025 · Mar 31, 2024 −$5.26M
Operating Income Q1 2025 · Mar 31, 2024 −$5.59M